Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.
Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.
Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.
Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, featuring a fireside chat on September 13 at 7:00 am ET. The second is the Cantor Global Healthcare Conference from September 27-30, 2021, with a formal presentation on September 30 at 8:40 am ET. Presenters include the company's CEO and scientific leaders. Webcast links for both events are available via Arbutus' website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced significant advancements in its hepatitis B virus (HBV) pipeline, particularly AB-729, showcased in four abstracts at the EASL International Liver Congress™. The drug received FDA authorization for a Phase 2a trial, focusing on safety and antiviral activity when combined with nucleos(t)ide analog therapy. The press release highlighted two new collaborations to evaluate AB-729’s combination potential. Financially, Arbutus reported a net loss of $22.7 million for Q2 2021, with cash reserves of $121.3 million, sufficient for operations into Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 4:05 PM ET. The fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. A live webcast will be accessible via the Investors section of Arbutus' website, with an archive available post-conference. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its plans to release its second quarter 2021 financial results on August 5, 2021, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19. A live webcast will be accessible on their website, and an archived version will be available post-event. Investors can dial in using designated numbers for domestic and international participants.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has received FDA authorization for its Investigational New Drug application to initiate a Phase 2a clinical trial for AB-729, targeting chronic hepatitis B virus (CHB) infection. The trial will evaluate the safety and efficacy of AB-729 in combination with nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a. The randomized trial aims to enroll 40 subjects and is expected to start this quarter, with the potential to establish AB-729 as a cornerstone therapy for CHB.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) announced a clinical trial collaboration to assess a combination therapy for chronic hepatitis B (CHB) patients receiving nucleos(t)ide reverse transcriptase inhibitors (NrtIs). The Phase 2a trial will evaluate the safety and efficacy of Arbutus’s AB-729 and Vaccitech’s VTP-300 in a double-blind study. Enrollment is projected for 40 subjects, with initiation expected in the second half of 2021. Positive results may lead to a larger Phase 2b trial.
Arbutus Biopharma (Nasdaq: ABUS) and Antios Therapeutics have signed a clinical collaboration to evaluate a triple therapy for chronic hepatitis B involving Arbutus' AB-729 and Antios' ATI-2173, along with Viread. This Phase 2a trial will assess safety, pharmacokinetics, immunogenicity, and antiviral activity in patients. The trial is slated to start in H2 2021, with Antios covering the costs and Arbutus supplying AB-729. Early results for ATI-2173 show promise as a potential backbone in curative regimens, while AB-729 has demonstrated positive safety and efficacy in prior studies.
Arbutus Biopharma has announced promising results for its HBV treatment candidate, AB-729, which achieved a mean HBsAg decline of -1.87 log10 IU/mL after 44 weeks. In a clinical trial, 75% of subjects receiving AB-729 at 60 mg every 4 weeks had HBsAg levels below 100 IU/mL. Additionally, AB-729 demonstrated a favorable safety profile and showed potential for increased immune responses. The company is set to initiate Phase 2a trials later this year. The efficacy and safety data support AB-729 as a leading candidate in chronic hepatitis B treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced acceptance of five abstracts for the International Liver Congress 2021, focusing on chronic hepatitis B virus (HBV) treatments. Key presentations include a late-breaker on the GalNAc-siRNA AB-729, demonstrating HBsAg suppression, and the preclinical profile of the HBV capsid inhibitor AB-836. A conference call is scheduled for June 28, 2021, to discuss these findings. Hepatitis B continues to pose significant health challenges globally, affecting over 250 million people.
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on chronic hepatitis B virus (HBV) and coronavirus therapies, announced participation in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 2, 2021, featuring a fireside chat at 9:00 am ET. Presenters include CEO William Collier and other executives. The second is the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 am ET, also featuring a fireside chat. Links to webcasts are available on their website.
